Once backed up by further investigations and trials that the high‐risk cases identified by the proposed model do benefit from additional chemotherapy, the tool will be translated to clinical use to be used as an alternative to gene expression based tests currently in guidelines for this intermediate category of ER+/HER2− BC. The gene discussed is ESR1; the disease is breast cancer.